STA Pharma completes clinical supply of PhoenixMD’s breast cancer treatment

By Maggie Lynch

- Last updated on GMT

(Image: Getty/kritchanut)
(Image: Getty/kritchanut)
Clinical trial supply for the first targeted treatment of triple-negative breast cancer completed through PhoenixMD and STA Pharmaceutical agreement.

The drug candidate from Phoenix Molecular Designs, PMD-026, the first RSK inhibitor therapy for triple-negative breast cancer (TNBC), will enter the clinic in an upcoming Phase I/Ib study in women with breast cancer in the third quarter of 2019. The drug will also enter a toxicology study for investigational new drug (IND) application purposes.

STA Pharmaceutical, a subsidiary of WuXI STA, completed the manufacturing of the clinical supply of the drug product after the two companies entered an agreement in March 2018. STA produced a multi-kg drug supply of the candidate under good manufacturing practices (GMP) practices which is sufficient to treat all patients in the clinical trial.

The collaboration, which PhoenixMD said was a critical part of advancing the drug candidate to the clinic, will continue as WuXi STA recently expanded its operations in the US to include capsule production under GMP regulatory compliance.  

According to Sandra Dunn, CEO of PhoenixMD, metastatic TNBC, for which PMD-026 is a treatment, is the most deadly type of breast cancer. She added that PMD-026 is the first drug to ever reach clinical use against this novel target.

As a ribosomal S6 kinase (RSK) inhibitor therapy, PMD-026 works on the kinase protein that drives the growth of the breast cancer subtype relative to the hormone positive or HER-2 positive breast cancer. The company stated that the candidate is also applicable to greater than 14 different types of cancers.

Related news

Show more

Related products

show more

Powered by Ingredients + Innovation

Powered by Ingredients + Innovation

Content provided by Univar Solutions USA | 07-Oct-2024 | Product Brochure

In partnership with our industry-leading supplier partners, Univar Solutions Pharmaceutical Ingredients is proud to introduce Powering Healthy Tomorrows.

Reliability, scale, and security of supply

Reliability, scale, and security of supply

Content provided by Univar Solutions USA | 28-Aug-2024 | Product Brochure

Univar Solutions Pharmaceutical Ingredients is proud to offer one of the most expansive portfolios of 15,000+ products, including high-purity solvents,...

Ultra Low Temperature Packaging solutions

Ultra Low Temperature Packaging solutions

Content provided by Almac Group | 12-Feb-2024 | Case Study

Advanced Therapy Medicinal Products (ATMPs) offer ground-breaking opportunities for treating injuries and disease, in particular for cases of severe, untreatable...

Related suppliers

Follow us

Products

View more

Webinars